Sanofi will pay Regeneron Pharmaceuticals $1 billion upfront — with up to $7 billion more in potential milestone payments — to expand their two-decade antibody collaboration into a new series of immunology drug candidates, the companies announced Thursday.

The structure of the deal reprises the division of labor that produced Dupixent, the interleukin-4/interleukin-13 blocker that became one of the best-selling drugs in the world. Regeneron will lead research and development; Sanofi will steer commercialization. The two companies will split profits on any resulting medicines evenly.

For R&D portfolio managers, the arrangement matters on two levels. First, it commits one of the industry's largest immunology franchises to a discovery-stage pipeline rather than to licensing mature or clinical-stage assets, effectively an $8 billion ceiling on pre-commercial science. Second, it consolidates Regeneron's position as the discovery engine — the Tarrytown, New York-based company keeps laboratory leadership while ceding sales execution to its Paris-based partner.

"By combining Regeneron's world-class scientific discovery and antibody development expertise with Sanofi's global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology," George Yancopoulos, Regeneron's chief scientific officer, said in a statement.

The phrase "once again" carries weight. Dupixent, approved first for eczema in 2017 and subsequently for asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and prurigo nodularis, generated the commercial case for this second act. The drug's sustained growth — it now anchors both companies' revenue — is the implicit data set behind Sanofi's willingness to write a 10-figure upfront check for a program series that has not yet disclosed a single clinical candidate.

The companies did not specify in the announcement how many antibodies the new series includes, which targets are involved, or when the first candidate would enter clinical trials. The $7 billion milestone component is likewise uncapped in public detail — it is unclear how the payments break down across development, regulatory and commercial milestones. Those gaps leave the headline economics open to scrutiny: the true cost to Sanofi depends entirely on how many programs survive the attrition that typically claims the majority of discovery-stage immunology assets.

What the deal does establish is the benchmark pricing for re-upping a proven alliance. The $1 billion upfront payment ranks among the larger commitments any large pharma has made to an early-stage collaboration this cycle, and it signals how incumbents now value guaranteed first access to a partner's discovery platform once that platform has produced one franchise-scale hit.

For Sanofi, the calculus is defensive as much as offensive. Dupixent faces eventual biosimilar exposure, and the company's immunology revenue concentration makes replenishing the pipeline a budget priority rather than a discretionary bet. Paying Regeneron to keep the antibody engine running buys continuity at a known cost structure — an even profit split — rather than competing at auction for external clinical-stage assets whose prices have inflated across the sector.

For Regeneron, the deal monetizes discovery capacity without diluting laboratory control. The company retains R&D leadership, meaning its internal scientists — under Yancopoulos — decide which targets advance and which die. That autonomy, paired with a 50% profit share on commercialized products, aligns with Regeneron's long-standing strategy of partnerships that fund its proprietary science rather than outsource it.

The announcement did not include an expected timeline for the first data readouts or candidate nominations, and neither company disclosed whether the new antibodies target mechanisms adjacent to Dupixent's Th2 pathway or address distinct immunological axes. The full financial terms beyond the upfront and milestone ceiling remain to be detailed in regulatory filings.

Both companies said the expanded collaboration aims to replicate the Dupixent model — discovery excellence paired with global commercial reach — across the new antibody series. Whether the second act can match the first will become clear as candidates emerge from the laboratory and into the clinic.